(Total Views: 817)
Posted On: 04/13/2025 6:28:08 PM
Post# of 154730
Going back about five years ago, GSK (ViiV and Shionogi) settled with Gilead (Biktarvy) regarding an infringement lawsuit...as a result Gilead agreed to pay upfront $1.25 BN and 3% royalty on future sales...
ViiV (child of GSK) is protected under US Patent 8,129,385 which expires on 5th of October 2027...about 30 months from now.
ViiV is a Global specialist company in HIV.
GSK (Emma Walmsley) could provide Cytodyn with a soft landing...after we launch.
The data about GSK/ViiV appears in SEC filings, Butt,...not in investor presentations...all of which might suggest a strategy to keep details confidential,...until a potential deal/arrangement is finalized.
Again,...just spitballin.
ViiV (child of GSK) is protected under US Patent 8,129,385 which expires on 5th of October 2027...about 30 months from now.
ViiV is a Global specialist company in HIV.
GSK (Emma Walmsley) could provide Cytodyn with a soft landing...after we launch.
The data about GSK/ViiV appears in SEC filings, Butt,...not in investor presentations...all of which might suggest a strategy to keep details confidential,...until a potential deal/arrangement is finalized.
Again,...just spitballin.
(7)
(0)
